Objective-In this study, we attempted to uncover the functional impact of and its target gene in smooth muscle cell (SMC) differentiation and delineate the molecular mechanism involved. Approach and Results-miR-22 was found to be significantly upregulated during SMC differentiation from embryonic stem cells and adventitia stem/progenitor cells. Enforced expression of miR-22 by its mimic, while knockdown of miR-22 by its antagomiR, promotes or inhibits SMC differentiation from embryonic stem cells and adventitia stem/progenitor cells, respectively. Expectedly, miR-22 overexpression in stem cells promoted SMC differentiation in vivo. Methyl CpGbinding protein 2 (MECP2) was predicted as one of the top targets of miR-22. Interestingly, the gene expression levels of MECP2 were significantly decreased during SMC differentiation, and MECP2 was dramatically decreased in miR-22 overexpressing cells but significantly increased when miR-22 was knockdown in the differentiating stem cells. Importantly, luciferase assay showed that miR-22 substantially inhibited wild-type, but not mutant MECP2-3′ untranslated regionluciferase activity. In addition, modulation of MECP2 expression levels affects multiple SMC-specific gene expression in differentiated embryonic stem cells. Mechanistically, our data showed that MECP2 could transcriptionally repress SMC gene expression through modulating various SMC transcription factors, as well as several proven SMC differentiation regulators. Evidence also revealed that enrichment of H3K9 trimethylation around the promoter regions of the SMC differentiation regulators genes were significantly increased by MECP2 overexpression. Finally, miR-22 was upregulated by platelet-derived growth factor-BB and transforming growth factor-β through a transcriptional mechanism during SMC differentiation.
S mooth muscle cells (SMCs) that form the walls of blood vessels not only provide the healthy vessel with its structure and ability to contract under normal conditions but also play a major role in the formation and progression of atherosclerotic plaques. It has been widely accepted that SMC differentiation is a critical process during cardiovascular development, and SMC proliferative related cardiovascular disease, such as atherosclerosis. Therefore, to better understand how vascular SMC differentiation being regulated is essential for improving the treatment or prevention of cardiovascular disorders and realizing the therapeutic potential of stem cells in cardiovascular regenerative medicine. Although recent findings reported from our group and others [1] [2] [3] [4] [5] [6] [7] have significantly improved our understanding regarding SMC differentiation and cardiovascular system development, the detailed molecular mechanisms of SMC differentiation from pluripotent stem cells have not been fully clarified. microRNAs (miRs) are endogenous, highly conserved, short noncoding 22 nucleotide RNAs and constitute a novel class of gene expression regulators which play important roles in various aspects of development, homeostasis, and disease. Interestingly, many miRs are reported to be expressed in a tissue-specific manner, suggesting that certain miRs might be important for cell/tissue specification. 8 In addition, studies using dicer or drosha deficient embryonic stem (ES) cells have suggested that miRs play a role in ES cell self-renewal and differentiation. [9] [10] [11] An essential role of miRs in cardiovascular development has been demonstrated in a study of Dicerdeficient mice which showed that the loss of miRs resulted in severe impairment of heart and blood vessel development. 12 Furthermore, it has been shown that conditional deletion of Dicer in vascular smooth muscle caused late embryonic lethality at embryonic day 16 to 17 because of decreased SMC proliferation and differentiation which resulted in thinner vessel walls, impaired contractility, and hemorrhage, 13, 14 highlighting the importance of miRs in SMC proliferation and differentiation. Although the disruption of miR processing during embryonic development provides important insights into the understanding of the functional involvements of miRs in cardiovascular development, manipulation of individual miRs may offer more precise answers to the significance and exact role of individual miRs in SMC differentiation because the elimination of virtually all miRs makes it impossible to identify relevant regulatory circuits and related miR targets. microRNA-22 (miR- 22) , has been originally suggested as tumor suppressor, [15] [16] [17] was found to play an important role in cardiovascular disease. It has been recently reported that miR-22 could contribute to cardiac aging by inducing cellular senescence and promoting migratory activity of cardiac fibroblasts trough targeting mimecan (osteoglycin). 18 Moreover, miR-22 is upregulated during human ES cell differentiation, implying that miR-22 could play a potential role in stem cell differentiation. 19 In the present study, we have demonstrated for the first time that miR-22 plays an important role in SMC differentiation from stem cells in vitro and in vivo by targeting methyl CpG-binding protein 2 (MECP2), a well-known epigenetic regulator. Furthermore, we have also provided compelling evidence to support that MECP2 is a potential transcriptional repressor for SMC-specific gene expression during SMC differentiation through an epigenetic modification mechanism.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

miR-22 Mediates SMC Differentiation From ES Cells In Vitro
To induce SMC differentiation, ES cells (ES-D3) were reseeded into collagen-coated flasks and cultured in SMC differentiation medium for 2 to 8 days as described in our previous studies. [1] [2] [3] [4] [5] [20] [21] [22] [23] Consistently, SMC-specific markers including smooth muscle α actin (SMαA) and myosin heave chain (smooth muscle-myosin heave chain for protein or SM-myh11 for gene) were significantly increased on cell differentiation ( Figure I in the online-only Data Supplement). Our recent study has suggested that microRNA-34a (miR-34a) plays a functional role in SMC differentiation. 24 Interestingly, along with miR-34a another miRNA, miR-22, was emerged as one of the top upregulated miRNAs during SMC differentiation in our miRNA microarrays analyses, 24 which was further confirmed by real-time quantitative polymerase chain rection analysis ( Figure 1A ), suggesting a role for miR-22 in SMC differentiation. To investigate whether miR-22 induction was important for SMC differentiation, lose-of-function experiments by using Anti-miR miR-22 inhibitor (Ambion) were performed in differentiating ES cells. Data showed that both gene and protein levels ( Figure 1B ; Figure IIA in the online-only Data Supplement) of smooth muscle differentiation-specific markers (SMαA, smooth muscle 22 α [SM22α], h1-calponin, and SM-myh11) were significantly inhibited by miR-22 knockdown. However, data from the gain-of-function experiments using Pre-miR mmu-miR-22 miRNA Precursor (Ambion) clearly revealed that miR-22 overexpression could enhance the gene and protein expression of SMC-specific markers ( Figure 1C ; Figure IIB in the online-only Data Supplement), suggesting a critical role of miR-22 in SMC differentiation from stem cells. Importantly, we also observed that 2 of important SMC transcription factors, serum response factor (SRF) and myocardin (Myocd), were regulated by miR-22 in a similar manner to SMC-specific genes, while modulation of miR-22 expression levels in differentiating ES cells has no effect on the expression level of another transcriptional factor myocyte enhancer factor 2C (MEF2c; Figure III in the online-only Data Supplement), suggesting that miR-22 works in concert with SRF and Myocd during SMC differentiation from stem cells. maintained in ES cell culture medium. No significant differences were observed between the sorted cells and their parent ES cells in terms of morphology, self-renew, and pluripotency when they were cultured in ES cell culture medium for up to at least 5 passages (data not shown). The expression level of miR-22 was low and similar among parental ES cells, control, and miR-22 overexpressing ES cells ( Figure IVB in the online-only Data Supplement), indicating that the expressional machinery of miR-22 was inhibited under stem cell culture condition. Similar to their parent cells, miR-22 expression was significantly upregulated during differentiation, and compared with control ES cells (pLL3.7-GFP), the expression levels of miR-22 in miR-22 overexpressing ES cells (pLL3.7-GFP-miR-22) were further upregulated at day 8 of differentiation ( Figure IVB in the online-only Data Supplement), suggesting that the inhibitory mechanism of miR-22 under stem cell culture condition has been removed and miR-22 was successfully upregulated in these cells during SMC differentiation. Consequently, more SMCs were differentiated from miR-22 overexpressing ES cells ( Figure IVC in the online-only Data Supplement), further confirming that miR-22 promotes SMC differentiation. To explore further the functional relevance of miR-22 in SMC differentiation in vivo, pLL3.7-GFP and pLL3.7-GFP-miR-22 ES cells were subcutaneously injected into C57BL/6J mice with 100 ng/mL of platelet-derived growth factor (PDGF)-BB to promote in vivo SMC differentiation as described in our previous studies. 1, 2 We observed that a higher percentage of cells were smooth muscle-myosin heave chain-positive SMCs in the implants of miR-22 overexpressing ES cells than that of control cells as demonstrated by immunofluorescence staining with antibody against GFP and smooth muscle-myosin heave chain ( Figure VA and VB in the online-only Data Supplement). As expected, the majority of cells in the Matrigel implants were GFP-positive, implying its exogenous origins ( Figure VA in the online-only Data Supplement). Furthermore, our data showed that the expression levels of miR-22, SMαA, and smooth muscle-myosin heave chain in the Matrigel implants of pLL3.7-GFP-miR-22 ES cells were significantly higher than that of control cells ( Figure contribute to atherosclerosis of vein-graft. 25 To explore further its relevance or implication of miR-22 in vascular diseases, adventitia stem cell antigen 1-positive cells isolated from vessel adventitia as described previously 2, 25 were induced to differentiate into SMCs. Real-time quantitative polymerase chain rection analyses showed that miR-22 was significantly upregulated during SMC differentiation from adventitia stem cell antigen 1-positive cells, along with various SMC differentiation genes ( Figure VIA in the online-only Data Supplement). Importantly, data from miR-22 overexpression and knockdown experiments ( Figure VIB and VIC in the online-only Data Supplement) revealed that enforced expression of miR-22 by its precursor significantly increased all the SMC genes examined, while knockdown of miR-22 by its antagomiR/ inhibitor dramatically inhibited these gene expression, respectively, suggesting a functional involvement of miR-22 in SMC specifications of the vascular residential stem/progenitor cells.
Functional Role of miR-22 in SMC Differentiation In Vivo
Target Gene, MECP2, Is Negatively Regulated by miR-22 Through the Binding Sites Within 3′ UTR
By using similar strategies as described in previous study, 26 MECP2 was predicted as one of the top targets of miR-22. First, bioinformatics search for putative miR-22 binding sites within the MECP2 mRNA by using several online free accessible computational algorithmic databases (eg, TargetScan 4.0 and PicTar) revealed that the seed sequence of miR-22 is predicted to hybridize to several regions of MECP2 3′ untranslated region (UTR), which is evolutionarily conserved among vertebrate species. Second, at least 4 highly conserved binding sites for miR-22 have been identified within MECP2 3′ UTR ( Figure VIIA and VIIB in the online-only Data Supplement). Finally, by using mFold software (http://mfold.rna.albany. edu/?q=DINAMelt/Two-state-melting), we also found a favorable minimum loop-free energy (−10.70 to −12.0 kcal/mol) in the formation of the miR-22:MECP2 3′ UTR duplex stemloop for all 4 miR-22 binding sites, suggesting that miR-22 is involved in translational repression of MECP2. As expected, MECP2 gene expressions were significantly downregulated ( Figure 2A ) and displayed a negative correlation with the gene expression levels of miR-22 during SMC differentiation ( Figure 1A ), suggesting that miR-22 may negatively regulate MECP2. Such notion has been firmly supported by the findings that MECP2 gene levels were significantly downregulated or upregulated by overexpression or inhibition of miR-22 in the differentiating ES ( Figure 2B ) or adventitia stem cell antigen 1-positive cells ( Figure VIB and VIC in the online-only Data Supplement), respectively. Furthermore, as shown in Figure  VC in the online-only Data Supplement, MECP2 gene expression levels in the Matrigel implants of pLL3.7-GFP-miR-22 ES cells were significantly lower than that of control cells, indicating that MECP2 was also negatively regulated by miR-22 during in vivo SMC differentiation. Expectedly, the protein levels of MECP2 were dramatically inhibited by miR-22 overexpression ( Figure 2C ; Figure Supplement), indicating that MECP2 is negatively regulated by miR-22 directly or indirectly. To distinguish these 2 possibilities, we first attempted to generate the miRNA reporter containing full length of MECP2 3′ UTR (≈8500 bps) but unsuccessful. Instead, 3 MECP2 3′ UTR reporters containing the segments spinning through the first 2 miR-22 binging sites (1567-2698), the third binding site (4142-4968), and the fourth binding site (8173-9137) were successfully generated in this study, designated as pmiR-Luc-MECP2-A, -B, and -C ( Figure VIIA and VIIB in the online-only Data Supplement), respectively. Data from our miRNA reporter assay showed that the activity of luciferase of reporter A and C, but not reporter B, was significantly downregulated by miR-22 overexpression ( Figure 2D ). Most importantly, the site-directed mutagenesis of the predicted miR-22-binding site(s) in the MECP2 3′ UTR reporter(s) experiments showed that the second (within reporter A) and fourth (within reporter C) binding sites are required for MECP2 3′ UTR reporter activity inhibition mediated by miR-22 ( Figure 2E ).
MECP2 Overexpression Abolished miR-22-Mediated SMC Gene Expressions
We have provided solid evidence to support that MECP2 is an authentic miR-22 target during SMC differentiation. To investigate the potential role of MECP2 in SMC differentiation, MECP2 knockdown in the differentiating ES cells was conducted by using specific MECP2 small interfering RNA. Data showed that MECP2 knockdown significantly upregulated SMC-specific marker expressions ( Figure 3A ), suggesting that MECP2 inhibition can recapitulate the 
Functional Importance of SRF-Binding Site Within SMC-Specific Genes in MECP2-Mediated SMC Gene Expression
We have demonstrated clearly that SMC-specific gene expression was repressed by MECP2 gene activation. To further explore the underlying molecule mechanism by which MECP2 regulates SMC gene expression, luciferase activity assays were conducted in differentiating ES cells using respective SMC gene promoter reporters, pGL3-Luc-SMαA and pGL3-Luc-SM22α. Data showed that the overexpression of MECP2 in differentiating ES cells significantly inhibited SMαA and SM22α gene promoter activities ( Figure IXA in the online-only Data Supplement), indicating that MECP2 over-expression can repress specific SMC gene expression at transcriptional level. Since the functional importance of SRF binding element (CArG) within promoter region of SMCspecific genes has been well-documented in SMC gene regulation, 27 we thus wondered if such elements also play a role in MECP2-mediated SMC gene repression. For such purpose, another set of luciferase assays using SRF binding site mutants (pGL3-Luc-SMαA-SRFmu and pGL3-Luc-SM22α-SRFmu) generated in our previous study 1 were carried out in differentiating ES cells. We observed that mutating the SRF binding element within SMC gene promoters almost completely nullified the inhibitory effects of MECP2 overexpression on SMC gene transcriptional activity ( Figure  IXA ), suggesting that SRF binding site(s) within the promoters is required for MECP2-mediated SMC gene repression. However, we observed no significant enrichment of MECP2 within the promoter regions of SMC genes as demonstrated by ChIP assays using MECP2-specific antibody ( Figure  IXB ), suggesting no direct binding of MECP2 to SMC gene promoters. Furthermore, as expected, although we observed a huge degree of SRF enrichment on SMC gene promoter (up to tenfold enrichment) in separate CHIP assays using SRF-specific antibody, such enrichment was not affected by MECP2 over-expression ( Figure IXC ), suggesting that MECP2 plays no significant role in modulation of SRF binding to SMC-specific gene promoters.
SMC Transcription Factors SRF and Myocd Are Transcriptionally Repressed by MECP2
Our previous data showed that the gene expression levels of SRF and Myocd, but not the MEF2c, were significantly regulated by miR-22 ( Figure III in the online-only Data Supplement). Importantly, data shown in Figure 4A revealed that these 2 transcription factors were regulated by MECP2 in . A, The expression levels of serum response factor (SRF) and myocardin (Myocd), but not the myocyte-specific enhancer factor 2c (MEF2c), were significantly downregulated by MECP2 overexpression. Total RNAs were harvested as described in Figure 3A . an opposite manner to miR-22, implying an important role of MECP2 in regulation of these 2 transcription factors during SMC differentiation. Such possibility has been clearly supported by the data obtained from luciferase activity assays using respective SRF, MEF2c, and Myocd gene reporter plasmids (pGL3-Luc-SRF, pGL3-Luc-MEF2c, and pGL3-Luc-Myocd) generated in our previous study 1 ( Figure 4B ). Interestingly, ChIP assays with MECP2 antibody showed a significant enrichment of MECP2 within the promoter regions of SRF (≤3-folds) and Myocd (≤20-folds), and such enrichments were further enhanced by MECP2 overexpression (Figure 4C ), suggesting that MECP2 directly binds to SRF and Myocd gene promoters. Taken together, our data clearly demonstrated that MECP2 transcriptionally repress SMC transcription factor gene expression during SMC differentiation from stem cells through its direct binding to their promoter regions.
Other SMC Differentiation Regulators Are Regulated by miR-22 and MECP2
Because transcription factor nuclear factor erythroid 2-related factor 3 (Nrf3), 5 NAPDH (nicotinamide adenine dinucleotide phosphate) oxidase 4 (Nox4), 21 platelet-activating factor acetylhydrolases (phospholipase A2, group VII [Pla2g7]), 2 histone deacetylases 7 (HDAC7), 20 and DNA/RNA-binding proteins (heterochromatin protein 1γ [Cbx3], 3 heterogeneous nuclear ribonucleoprotein A2B1 4 and A1 1 ) have been previously identified as important SMC differentiation regulators in our SMC differentiation system, therefore, we wondered whether miR-22 and MECP2 play any role in regulation of these genes. To this aim, the gene expression levels of above SMC differentiation regulators were examined in the cells overexpressing miR-22 or MECP2. We found that the gene expression levels of Nox4, HDAC7, and Pla2g7 were consistently regulated by miR-22 ( Figure 5A ) and MECP2 ( Figure 5B ) in an opposite way. Importantly, these 3 genes were coregulated by miR-22 and MECP2 in a similar manner to other SMC differentiation genes ( Figure VIII in the onlineonly Data Supplement), suggesting miR-22-and MECP2mediated SMC differentiation at least partially through regulation of these 3 reported SMC differentiation modulators. Furthermore, data from luciferase assays using a functional Pla2g7 gene promoter reporter (pGL3-Luc-Pla2g7-P2, harboring 387 bps of Pla2g7 gene promoter fragment located between ≈2.4 and 2.0 kb upstream of the translation start site of Pla2g7 gene) and a control reporter (pGL3-Luc-Pla2g7-P10, located within exon 1 of Pla2g7 gene) generated in our previous study 2 showed that the promoter activity of pGL3-Luc-Pla2g7-P2, but not pGL3-Luc-Pla2g7-P10, was significantly regulated by MECP2 overexpression ( Figure 5C ). Finally, ≤4 times of MECP2 enrichment within Pla2g7 gene promoter (region 2) was observed, and MECP2 overexpression further Figure 1C . B, Three reported SMC differentiation regulators were regulated by MECP2. Total RNAs were harvested as described in Figure 3A . increased the accumulation of MECP2 within Pla2g7 gene promoter, while no apparent enrichment of MECP2 within the adjacent promoter area (region 10) was observed in the MECP2-ChIP assays ( Figure 5D ), suggesting that MECP2 regulates Pla2g7 gene expression through direct interaction with the region 2 (−2.4 to −2.0 kb) of Pla2g7 gene promoter. Similarly, both Nox4 and HDAC7 were regulated by MECP2 through a transcriptional mechanism as demonstrated in promoter activity analyses ( Figure XA 
MECP2 Represses SMC Gene Expression Through Increasing H3K9 Methylation Within the Gene Promoters of SRF, Myocd, and Pla2g7
It has been well-documented that MECP2 is capable of binding specifically to methylated DNA and involves in gene silencing, and methylation of lysine H3K9 is closely associated with gene transcriptional repression. 28 To elucidate further the molecular mechanism by which MECP2 represses SMC gene expression, we first examined if histone H3 trimethyl Lys9 (H3K9me3) expression levels were regulated by MECP2. Data from overexpression experiments showed that H3K9me3 protein expression levels were not significantly affected by MECP2 overexpression (Figure 6A ). However, our ChIP assays with H3K9me3-specific antibody showed a variety of degree of H3K9me3 enrichment within the promoter regions of examined genes (≤2.5-folds for SMαA/SM22α; 23-folds for SRF, 40 times for Myocd, and 96 times for Pla2g7, respectively), and importantly such enrichments were further enhanced by MECP2 overexpression for SRF, Myocd, and Pla2g7 gene promoters ( Figure 6C and 6D ), but not for SMαA/SM22α ( Figure 6B ), which are consistent with the enrichment of MECP2 within respective gene promoters as observed in our above ChIP assays with MECP2 antibody ( Figure IXB in the online-only Data Supplement; Figures 4C and 5D ). Expectedly, miR-22 overexpression significantly inhibited H3K9me3 enrichment within the promoter regions of SRF, Myocd, and Pla2g7, but no such inhibition was observed within the promoter regions of SMαA/SM22α ( Figure XI in the online-only Data Supplement). Taken together, above data clearly demonstrated that MECP2 represses SMC-specific gene expression, at least partially through increasing H3K9 trimethylation within the gene promoters of SMC-specific transcription factors (SRF and Myocd) and differentiation modulators (eg, Pla2g7).
PDGF-BB and TGF-β Upregulate miR-22 Through a Transcriptional Mechanism
Our previous studies have suggested that during stem cell differentiation, auto-secreted growth factors (eg, PDGF-BB 20,23 Figure 6 . Methyl CpG-binding protein 2 (MECP2) modulates histone H3 trimethyl Lys9 (H3K9me3) enrichment on the respective gene promoter regions of serum response factor (SRF), myocardin (Myocd), and phospholipase A2, group VII (Pla2g7). A, H3K9me3 protein levels were not affected by MECP2 overexpression. Total proteins were harvested as described in Figure 3B . and transforming growth factor [TGF]-β 21 ) from the differentiating cells activate their respective down-stream signal pathways, which in turn trigger SMC differentiation program. We wondered if miR-22 was one of such signal molecules during SMC differentiation. Real-time quantitative polymerase chain rection analyses showed that both PDGF-BB and TGF-β were significantly upregulated miR-22 expression in a dose-dependent pattern ( Figure XIIA and XIIB in the online-only Data Supplement). Moreover, PDGF-BB and TGF-β treatments also increased the expression levels of miR-22 precursor and primary RNAs ( Figure XIIC and XIID in the online-only Data Supplement), suggesting that miR-22 was regulated by PDGF-BB and TGF-β at transcriptional level. Such a notion was further confirmed by incubating the cells with RNA synthesis inhibitor, actinomycin D (1 μg/mL for 6 hours), in which the data showed that Actinomycin D incubation ablated the effect of PDGF-BB and TGF-β treatments on the expression levels of miR-22 ( Figure XIIE and XIIF in the online-only Data Supplement).
Discussion
Accumulating evidence in the literature has revealed that the gene regulatory program of SMC differentiation from pluripotent stem cells is orchestrated by a coordinated molecular network composing of various signaling pathways and molecules, such as Myocd-SRF complex, extracellular matrix, integrins, retinoid receptor, TGF family, notch family, reactive oxygen species, miRs, HDACs, and others (eg, paired-like homeodomain 2 and protein inhibitor of activated STAT-1). 29, 30 Despite enormous efforts have been put into this field in the past decades, our understandings into the molecular mechanisms underlying SMC differentiation are still far from complete. In the present study, we have further advanced our knowledge in this topic by uncovering an important role for miR-22 in regulating SMC-specific gene expression and SMC differentiation from murine ES cells in vitro and in vivo. Furthermore, we present the first evidence of a functional role for MECP2 in SMC differentiation and SMC-specific gene regulation. Importantly, we have provided compelling evidence to support that the identified target gene, MECP2, functions as an important SMC differentiation gene repressor during SMC differentiation from stem cells. It has been reported that the human miR-22 gene, located in a minimal loss of heterozygosity region between markers D17S1866 and D17S1574 on chromosome 17 (17p13.3) (close to TP53) in cancer cells, overlaps the exon 2 region of the spliced noncoding C17orf91 transcript, 31 and the primary miR-22 is processed from a capped, polyadenylated transcript, 32 while the mouse counterpart is also mapped to a cancer-associated genomic region, 33 implying an important role for miR-22 in cancers. Several studies have independently identified miR-22 as a tumor suppressor. [15] [16] [17] Moreover, it has been recently reported that miR-22 could contribute to cardiac aging by inducing cellular senescence and promoting migratory activity of cardiac fibroblasts through targeting osteoglycin, 18 suggesting that miR-22 might play a role in cardiovascular disease. Furthermore, it has been documented that miR-22 is upregulated during human ES cell differentiation, 19 induced by TPA (12-O-tetradecanoylphorbol-13-acetate) during monocytic differentiation from HL-60 leukemia cell lines, 34 and is close associated with erythroid maturation, 35 implying that miR-22 could play a potential role in hematopoietic cell differentiation and maturation. However, the functional role of miR-22 in SMC differentiation from pluripotent stem cells remains to be explored. In the present study, miR-22 has been signaled out from our miR screening experiments as one of the top potential miRNA candidates with high expression levels during SMC differentiation from ES cells. Importantly, by using miRNA gain/lose-of function analyses, we confirmed a critical role for miR-22 in SMC differentiation from ES cells in vitro. Furthermore, by generating miR-22 overexpressing ES cell lines and using our well-established in vivo SMC differentiation model (Martigel-stem cells-PDGF-BB complex implantation), 1, 2 we provide first evidence to support that miR-22 plays an important role in embryonic SMC differentiation in vivo. These data firmly demonstrated for the first time that miR-22 is an important SMC differentiation regulator.
Identifying and validating the genuine mRNA target(s) that are responsible for or mediate any given functions of examined miRNA(s) is fundamental and most difficult step in miRNA study. Because we have demonstrated clearly that miR-22 can regulate SMC differentiation in vitro and in vivo, we sought to identify the downstream mRNA target(s) which is responsible for miR-22 mediated SMC differentiation from stem cells. For this purpose, we used several computational algorithmic databases including Targetscan (www.targetscan. org), pictar (www.pictar.mdc-berlin.de), and miRanda (www. microrna.org) to predict the putative mRNA targets of miR-22 and found that MECP2 was emerged as a top targets of miR-22. Interestingly, the MECP2 mRNA has a long 3′ UTR of ≈8.7 kb which bears evolutionarily conserved miRNA target sites, suggesting that it might be regulated by miRNAs. Importantly, we have identified 4 highly conserved binding sites for miR-22 within MECP2 3′UTR as shown in Figure  VIIA and VIIB in the online-only Data Supplement, implying that MECP2 is an mRNA target of miR-22. Such notion that MECP2 is a bona-fide miR-22 target during SMC differentiation has been supported by several lines of evidence: First, MECP2 gene expression was significantly downregulated during SMC differentiation from stem cells (Figure 2A ), which displayed a perfect and negatively association with miR-22 expression levels ( Figure 1A) . Second, MECP2 gene and protein expression levels were adversely regulated by miR-22 as demonstrated in miR-22 overexpression and inhibition experiments ( Figure 2B and 2C) . Third, miR-22 overexpression dramatically downregulates MECP2 3′ UTR activity, but such downregulation was completely abolished when 2 of the miR-22 binging sites within MECP2 3′ UTR were mutated ( Figure 2D and 2E) . Interestingly, the binding sites that have been proven to be responsible for miR-22-mediated MECP2 gene regulation in this study are the ones located around ≈2797 bp and ≈8347 bps, but not the one located in the middle of 3′ UTR (≈4537 bp), which is consistent with one of the principal rules of miR-mRNA interactions that for gene with long 3′ UTRs, the position of miRNA-binding site(s) that is not too far away from the poly(A) tail or the termination codon can significantly improve site efficacy, 36 therefore represents a higher possibility of these binding sites being more functional relevance. However, it is noteworthy to mentioned that because we failed to obtain such a mutant with only first miR-22-binding site (≈1577 bp) being mutated in this study, we could not exclude the importance of this binding site in mediating MECP2 3′ UTR activity by miR-22. Nonetheless, our data clearly demonstrated that MECP2 is a genuine mRNA target of miR-22. Finally but importantly, comparing with the Matrigel plugs implanted with control ES cells, the MECP2 gene expression levels in the Matrigel implants with miR-22 overexpressing ES cells were much lower ( Figure VC in the online-only Data Supplement), suggesting that MECP2 gene expression is negatively regulated by miR-22, and MECP2 is also a true mRNA target of miR-22 during in vivo SMC differentiation from stem cells.
Apart from MECP2 that has been identified and validated as a bona-fide miR-22 mRNA target during SMC differentiation in the current study, several other miR-22 mRNA targets, including oncogene EVI-1 (ecotropic viral integration site 1), 37 HDAC4, 38 PTEN (phosphatase and tensin homolog), 39 estrogen receptor α, 40 c-Myc binding protein, 33 MYC associated factor X, 34 TET2 (tet methylcytosine dioxygenase 2), 41 have been reported in cancer cells. However, none of them was proved to be a true miR-22 mRNA target in our SMC differentiation system. Among them, only the expression levels of EVI-1 was negatively associated with miR-22 expression levels in the miR-22 overexpression and inhibition experiments, but overexpression of miR-22 failed to downregulate ZVI-1 (ecotropic viral integration site 1) 3′ UTR luciferase activity (data not shown). These data suggested such a possibility that some of miR-22 mRNA targets are cell-specific or miR-22 likely plays a divergent role under various physiological and pathological conditions through targeting distinct target gene(s).
One of novel mechanistic findings in the present study is that we provided first time but compelling evidence to support that MECP2 repression is required for miR-22 mediated SMC differentiation from stem cells, and MECP2 functions as an inhibitory regulator in SMC differentiation gene expression. MECP2 is the funder member of methyl-CpG-binding domain proteins that can specifically bind to both methylated and unmethylated DNA and recruit distinct interacting protein partners to establish a repressive or active chromatin environment, 42 respectively, and has been reported to be involved in a variety of biological functions and diseases, such as Rett syndrome and neural development, 43, 44 modulating human inducible nitric oxide synthase gene expression, 45 regulation of myofibroblast differentiation during pulmonary fibrosis, 46 myogenesis, 47 neural differentiation from ES cells 48 or neural precursors, 49 adult neurogenesis, 50 neuron electrophysiological properties, 51 and embryonic development. 52 Importantly, recent study has suggested that MECP2 can switch their transcriptional activity in the epigenetic regulation of neural chromatin and gene expression through binding hydroxymethylcytosine-or 5-methylcytosine-containing DNA with a similar affinity. It has been reported that MeCP2 binding to hydroxymethylcytosine can facilitate transcription in neural cell types while at the same time acting in repression when bound to 5-methylcytosine-containing DNA. 53 In the present study, we have provided compelling evidence to support that MECP2 is an important SMC differentiation mediator by transcriptional regulation of the gene expression of SMCspecific markers, transcriptional factors, and other SMC differentiation regulators. To date several molecular roles have been described for MeCP2 in gene regulation: transcriptional repression, activation of transcription, nuclear organization, and splicing. 42 In consistent its roles in gene regulation, we have provided strong evidence in the current study which firmly demonstrated that MECP2 is a transcription repressor to regulate SMC-specific gene expression (SMαA, SM22α, SRF, Myocd, Nox4, HDAC7, and Pla2g7) during SMC differentiation (Figures 4 and 5 Another important finding of the present study is that we further demonstrate that MECP2 acts as a potential transcriptional repressor for SMC gene regulation through modulating epigenetic modifications of SMC-specific transcription factors and SMC differentiation modulators. DNA methylation and histone modifications represent the major epigenetic mechanisms implicated in the regulation of gene transcription in mammals. It has been widely accepted that hypomethylation of the DNA surrounding the proximal promoter region is a prerequisite for gene activation, whereas heavy methylation leads to gene silencing. Previous studies reported that MeCP2 was associated with histone methyltransferase activity in vivo, and such activity is directed against Lys9 of histone H3. 54 Moreover, our previous data also showed that H3K9 methylation was enriched within SMC-specific gene promoter regions in the differentiating stem cells. 3 These data prompted us to investigate if MECP2 represses SMC-specific gene expression during stem cell differentiation is through modulating DNA methylation. In the current study, we have provided for the first time evidence to support a notion that instead of increasing H3K9me3 protein production in the differentiating stem cells, MECP2 increases H3K9 trimethylation within the gene promoters of SMC-specific transcription factors and other SMC differentiation regulators, resulting in SMC gene repression during stem cell differentiation toward SMC lineage. However, the functional involvements of MECP2 in the regulation of other epigenetic modifications remain to be fully elucidated.
Finally, we have demonstrated that miR-22 is upregulated by PDGF-BB and TGF-β through a transcriptional mechanism during SMC differentiation. Interestingly, apart from miR-22, our unpublished data suggest that PDGF-BB and TGF-β also transcriptionally upregulates another reported SMC differentiation miRNA, miR-34a. 24 Taken together, we have successfully identified a novel function of miR-22 in SMC differentiation from stem cells in vitro and in vivo and provided comprehensive evidence to support that MECP2 is a genuine mRNA target of miR-22 during SMC differentiation, and repression of MECP2 in the differentiating stem cells is required for miR-22 mediated SMC differentiation. Moreover, we have revealed that MECP2 regulates SMC gene expression through a transcriptional mechanism, as well as an epigenetic signal pathway. Furthermore, we have found that miR-22 and MECP2 modulate SMC-specific gene expression through regulating other proven SMC differentiation masters, and have exemplify demonstrated that MECP2 transcriptionally regulates other SMC differentiation modulators gene expression through its direct binding to their promoter region and increasing H3K9 trimethylation within the gene promoters. Therefore, based on the findings presented in the current study and our previous study, 24 we propose the following molecular mechanism through which miRNAs mediate SMC differentiation ( Figure XIII in the online-only Data Supplement): during stem cell differentiation, miR-22 and miR-34a were transcriptionally upregulated by PDGF-BB and TGF-β autosecreted from differentiating cells. Consequently, the inhibitory effects of MECP2 on SMC-specific transcription factors (SRF and Myocd), as well as other SMC differentiation master regulators (eg, Pla2g7, Nox4 and HDAC7), were removed/ derepressed by upregulated miR-22, triggering SMC-specific gene expression program and promoting SMC differentiation. Simultaneously, increased miR-34a upregulated its target gene, NAD-dependent deacetylase sirtuin-1, through an unusual manner, which in turn transcriptionally regulated 3 SMC transcriptional factors (SRF, Myocd, and MEF2c), resulting in SMC differentiation gene activation and SMC differentiation. Undoubtedly, the findings presented in this study will significantly increase our knowledge of the molecular mechanisms underlying SMC differentiation and benefit future stem cell application in cardiovascular regenerative medicine.
